Image

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Study of Radiation Therapy for Lung Cancer with Limited Spread

Recruiting
18 years and older
All
Phase N/A
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates the use of stereotactic ablative radiotherapy (SABR) in patients with oligo-metastatic non-small cell lung cancer (NSCLC). It focuses on both synchronous and metachronous oligo-metastatic conditions, which are characterized by a limited number of metastatic lesions.

The purpose of this study is to evaluate the safety and effectiveness of SABR in controlling tumor growth and improving survival rates. The study will explore how SABR, when combined with targeted therapies or immunotherapy, can potentially enhance treatment outcomes for patients with NSCLC.

  • Who can participate: Adults with histologically confirmed non-small cell lung cancer (NSCLC) who have synchronous or metachronous oligo-metastatic disease are eligible. Participants must have an ECOG Performance Status of 0-2 and at least one target lesion suitable for SABR treatment.
  • Study details: Participants will undergo stereotactic ablative radiotherapy (SABR) to target all visible cancer sites. In some cases, SABR will be combined with targeted therapies or immunotherapy. A placebo is not used in this study.
Print
Study details
    NSCLC
    NSCLC Stage IV
    Oligometastatic Disease
    Non Small Cell Lung Cancer
    Non Small Cell Lung Cancer Metastatic
    EGF-R Positive Non-Small Cell Lung Cancer
    NSCLC Stage IV Without EGFR/ALK Mutation
    Non-Small Cell Adenocarcinoma
    Non-Small Cell Squamous Lung Cancer
    Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
    Synchronous Metastases
    Metachronous Metastasis

NCT06207292

Radiotherapy Oncology Centre "Santa Maria" Hospital

28 August 2025

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.